Isoglycyrrhizinate - Chia Tai Tianqing Pharmaceutical

Drug Profile

Isoglycyrrhizinate - Chia Tai Tianqing Pharmaceutical

Alternative Names: Ganmei; Magnesium isoglycyrrhizinate; Tianqing Ganmei; Tianqingganmei; Yigancaosuanmei Zhusheye

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Developer Chia Tai Tianqing Pharmaceutical Group; Shanghai Jiao Tong University
  • Class Anti-inflammatories; Saponins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic hepatitis; Liver disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Liver-disorders (In volunteers) in China (IV, Infusion)
  • 14 Apr 2016 Launched for Liver disorders and Chronic hepatitis in China (IV) before April 2016 (Chia Tai Tianqing Pharmaceutical Group website, April 2016)
  • 14 Apr 2016 Adverse events data from a phase III trial in Liver disorders released by Chia Tai Tianqing Pharmaceutical Group (IV, Injection) (Chia Tai Tianqing Pharmaceutical Group website, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top